TD Asset Management Portfolio holdings
AUM
$117B
1-Year Return
25.17%
This Quarter Return
+2.58%
1 Year Return
+25.17%
3 Year Return
+87.06%
5 Year Return
+156.45%
10 Year Return
+305.53%
AUM
$107B
AUM Growth
-$263M
(-0.24%)
Cap. Flow
-$1.19B
Cap. Flow
% of AUM
-1.11%
Top 10 Holdings %
Top 10 Hldgs %
25.85%
Holding
1,451
New
70
Increased
678
Reduced
517
Closed
90
Top Buys
| 1 |
Apple
AAPL
|
$328M |
| 2 |
Exxon Mobil
XOM
|
$206M |
| 3 |
Danaher
DHR
|
$169M |
| 4 |
Carlisle Companies
CSL
|
$109M |
| 5 |
iShares MSCI EAFE ETF
EFA
|
$108M |
Top Sells
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$223M |
| 2 |
NVIDIA
NVDA
|
$184M |
| 3 |
iShares 20+ Year Treasury Bond ETF
TLT
|
$184M |
| 4 |
Accenture
ACN
|
$137M |
| 5 |
Visa
V
|
$115M |
Sector Composition
| 1 | Technology | 21.93% |
| 2 | Financials | 18.71% |
| 3 | Healthcare | 11.45% |
| 4 | Industrials | 10.26% |
| 5 | Consumer Discretionary | 7.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1326
Frontline
FRO
$4.85B
| $258K | ﹤0.01% |
9,840
+871
| +10% | +$22.9K |
|
|
ACB
1327
Aurora Cannabis
ACB
$272M
| $255K | ﹤0.01% |
+55,204
| New | +$255K |
|
1328
Catalyst Pharmaceutical
CPRX
$2.42B
| $254K | ﹤0.01% |
+16,400
| New | +$254K |
|
1329
AdvanSix
ASIX
$565M
| $250K | ﹤0.01% |
10,900
-8,800
| -45% | -$202K |
|
1330
Prime Medicine
PRME
$606M
| $239K | ﹤0.01% |
46,434
-82,588
| -64% | -$425K |
|
1331
Liberty Global Class C
LBTYK
$4.14B
| $230K | ﹤0.01% |
12,873
-15,972
| -55% | -$285K |
|
1332
Vanguard Value ETF
VTV
$144B
| $229K | ﹤0.01% |
1,426
| – | – |
|
1333
Baidu
BIDU
$33.8B
| $223K | ﹤0.01% |
2,583
| – | – |
|
1334
Cathay General Bancorp
CATY
$3.48B
| $211K | ﹤0.01% |
5,600
-10,100
| -64% | -$381K |
|
1335
Cross Country Healthcare
CCRN
$446M
| $210K | ﹤0.01% |
15,200
-2,900
| -16% | -$40.1K |
|
1336
Lindsay Corp
LNN
$1.5B
| $209K | ﹤0.01% |
1,700
| – | – |
|
1337
Stride
LRN
$7.08B
| $204K | ﹤0.01% |
2,900
-6,200
| -68% | -$437K |
|
1338
Green Dot
GDOT
$759M
| $202K | ﹤0.01% |
21,400
-3,800
| -15% | -$35.9K |
|
|
BCPC
1339
Balchem Corporation
BCPC
$5.24B
| $200K | ﹤0.01% |
+1,300
| New | +$200K |
|
1340
Liberty Global Class A
LBTYA
$4.06B
| $195K | ﹤0.01% |
11,165
+500
| +5% | +$8.72K |
|
1341
Immuneering
IMRX
$233M
| $193K | ﹤0.01% |
150,876
| – | – |
|
1342
KE Holdings
BEKE
$21.9B
| $187K | ﹤0.01% |
13,192
| – | – |
|
1343
Sally Beauty Holdings
SBH
$1.4B
| $182K | ﹤0.01% |
17,000
+2,400
| +16% | +$25.8K |
|
1344
Ginkgo Bioworks
DNA
$691M
| $174K | ﹤0.01% |
13,046
| – | – |
|
1345
AMC Networks
AMCX
$319M
| $173K | ﹤0.01% |
17,900
| – | – |
|
1346
TEGNA Inc
TGNA
$3.41B
| $167K | ﹤0.01% |
12,000
| – | – |
|
1347
Day One Biopharmaceuticals
DAWN
$759M
| $149K | ﹤0.01% |
10,796
| – | – |
|
1348
Hafnia
HAFN
$3.02B
| $148K | ﹤0.01% |
+17,567
| New | +$148K |
|
1349
Mitsubishi UFJ Financial
MUFG
$175B
| $142K | ﹤0.01% |
13,104
-1,486
| -10% | -$16K |
|
1350
ASE Group
ASX
$22.4B
| $126K | ﹤0.01% |
11,037
-132
| -1% | -$1.51K |
|